A nuclear complex of rictor and insulin receptor substrate-2 is associated with albuminuria in diabetic mice

Baljit K Singh1, Amoolya Singh, Desmond D Mascarenhas

  • 1Mayflower Organization For Research and Education, Sunnyvale, California 94085, USA. desmond@mayflowerworld.org

Abstract

Insights

Novel peptides nephrilin and anephril reduce albuminuria in diabetic mice by targeting key signaling pathways. Nephrilin shows promise as a safe intervention for diabetic kidney disease, impacting insulin receptor substrate-2 and protein kinase C signaling.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Diabetic nephropathy pathogenesis involves complex signaling pathways.
  • Investigating shared signaling events triggered by albuminuria-inhibiting peptides nephrilin and anephril may elucidate disease mechanisms.

Purpose of the Study:

  • To identify common signaling events associated with albuminuria in diabetic kidney disease.
  • To evaluate the efficacy and safety of nephrilin and anephril in preclinical models of diabetic nephropathy.

Main Methods:

  • Administration of nephrilin and anephril to diabetic mouse models (db/db and STZ-treated DBA/2J).
  • Measurement of urinary albumin, plasma glucose, and tissue protein markers (IRS2, p-PKC, SGK1) using ELISA.
  • Histological analysis and in vitro studies with kidney cells treated with glycated hemoglobin.

Main Results:

  • Both peptides significantly reduced albuminuria in diabetic mice without altering glucose or insulin levels.
  • Nephrilin and anephril decreased kidney levels of IRS2 and p-PKC; nephrilin also reduced splenic SGK1.
  • Nephrilin inhibited nuclear accumulation of IRS2 and p-PKC in kidney cells and showed no significant toxicity in safety studies.

Conclusions:

  • A subset of signaling markers, including mTORC2::IRS complexes, are closely linked to albuminuria.
  • Nephrilin demonstrates potential as a safe therapeutic agent for diabetic kidney disease by modulating key signaling pathways.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.